Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2019 02/15/2019 02/19/2019 02/20/2019 02/21/2019 Date
66.37(c) 67.59(c) 66.76(c) 66.98(c) 65.55(c) Last
5 737 099 6 214 220 6 396 202 5 679 808 5 607 851 Volume
+0.65% +1.84% -1.23% +0.33% -2.13% Change
More quotes
Financials (USD)
Sales 2019 21 974 M
EBIT 2019 11 241 M
Net income 2019 6 595 M
Debt 2019 6 341 M
Yield 2019 3,86%
Sales 2020 22 514 M
EBIT 2020 11 480 M
Net income 2020 7 234 M
Finance 2020 4 131 M
Yield 2020 4,19%
P/E ratio 2019 12,76
P/E ratio 2020 11,51
EV / Sales2019 4,15x
EV / Sales2020 3,58x
Capitalization 84 797 M
More Financials
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.3%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (90.9% of net sales) and other (9.1%; primarily... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
02/19GILEAD SCIENCES : Receives Approval in Canada for YESCARTA™ (Axicabtagene ..
AQ
02/14GILEAD SCIENCES : Stock Slides Lower on NASH Drug Failure
AQ
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/12Coty and Electronic Arts surge while Molson Coors dips
AQ
02/12GILEAD SCIENCES : Announces Topline Data from Phase 3 STELLAR-4 Study of Selonse..
AQ
02/11GILEAD SCIENCES : Announces Topline Data From Phase 3 STELLAR-4 Study of Selonse..
BU
02/08GILEAD SCIENCES : Report
CO
02/05GILEAD SCIENCES : Ralph Lauren surges, Gilead sinks
AQ
02/05Merck KGaA, GSK Enter Immuno-Oncology Deal Worth Up to $4.23 Billion -- Updat..
DJ
02/04GILEAD SCIENCES : Raises Dividend by 6 Cents a Share
DJ
More news
Analyst Recommendations on GILEAD SCIENCES
More recommendations
Sector news : Bio Therapeutic Drugs
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
RE
More sector news : Bio Therapeutic Drugs
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,7 $
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.73%84 797
VERTEX PHARMACEUTICALS13.49%48 023
REGENERON PHARMACEUTICALS13.51%45 363
GENMAB-5.57%9 415
SAREPTA THERAPEUTICS INC25.12%9 393
BLUEBIRD BIO INC38.14%7 298